p73和p53在肾癌中的表达及其意义  

Clinicopathological Significance of p73 and p53 Expression in Renal Cell Carcinoma

作　　者：邱国战[1] 周洪革[1] 李旭东[1] 

机构地区：[1]沈阳医学院附属中心医院泌尿外科,辽宁沈阳110024

出　　处：《沈阳医学院学报》2004年第2期68-70,共3页Journal of Shenyang Medical College

摘　　要：目的:探讨p73、p53蛋白在肾癌中的表达及其相关性及与肾癌临床分期、病理分级、预后之间的关系。方法:采用免疫组织化学技术对46例肾癌p73、p53表达进行对比研究。结果:p73、p53蛋白阳性表达与各病理类型、病理分级之间差异元显著性(P>0.05)。p73、p53蛋白阳性表达与临床分期之间差异有显著性(P<0.05)。p73与p53蛋白共同阳性表达与肾癌患者预后显著相关(P<0.05)。结论:p73和p53阳性表达与肾癌病理类型、病理分级无关而与临床分期有关。肾癌p73和p53共同阳性表达患者生存率明显低于其余患者,可能是判断肾癌预后的指标之一。Objective:To explore the expression of p73 protein and p53 protein in renal cell carcinoma (RCC) and analyze the correlation among clinical stage, pathologic grade and prognosis in RCC. Methods:Immuno histochemical method was used in 46 cases of RCC. Results: No significant correlation was found among p73, p53 positive expression and pathologic type, pathologic grade ( P > 0.05 ). p73 and p53 were positively related to the clinical stage ( P < 0.05 ). There was good correlation between the positive expression of p73 and p53 proteins and prognosis in RCC. Conclusion: The positive expression of p73 and p53 protein has no relation with pathologic type and pathologic grade, but with clinical stage. The survival rate of the patients with p73,p53 positive expression was significantly lower than that of the other patients, which might have a practical significance in assessing the prognosis of RCC.

关 键 词：P73 P53 肾癌 临床分期 病理分级 预后 

分 类 号：R737.11[医药卫生—肿瘤]